Latest News & Features
Regulation & Industry
The Third Circuit has upheld Thomson Reuters’ victory over Ross Intelligence in the first US appellate ruling on whether AI training can qualify as fair use. With the court’s reasoning still sealed, the case could have significant implications for AI developers using copyrighted content to build competing products. 30 September 2026
Biotech
The gene-editing company has accused a former employee of secretly co-founding a Chinese biotech while still at the company, in a trade secrets lawsuit involving rival base-editing therapies and disputed patent filings. 29 September 2026
Careers
As partner and head of IP for the region, the Hong Kong-based hire brings extensive experience advising on the IP aspects of complex corporate transactions and investments. 29 September 2026
Pharma
Can a drug’s ‘inactive’ precursor qualify for a multi-million pound patent extension? The UK High Court has just delivered a ruling on Takeda's ADHD drug Elvanse, weighing regulatory precedent against a conflicting German decision. 28 September 2026
Careers
The returning shareholder’s work spans the patent lifecycle and includes computerised business methods, polymer compositions, and small molecules. 28 September 2026
Pharma
Another Wegovy patent has been drawn into the long-running dispute between Mylan and Novo Nordisk over proposed generic versions of the weight-loss drug. 25 September 2026
Pharma
An Entresto Orange Book listing has survived a challenge in the US, while two trademark disputes handed Novartis contrasting fortunes at a European court. 24 September 2026
Careers
Following the prominent patent judge’s promotion to the Court of Appeal, the judiciary has appointed a King’s Counsel with 35 years’ experience as a barrister. 23 September 2026
Careers
Varnum appoints the new partner to its litigation and ADR practice team as a partner in Michigan, bringing industry expertise in software, medical devices, robotics, consumer electronics and more. 23 September 2026
Pharma
After a run of UK decisions going against major pharma patents on plausibility, Novartis bucked the trend with Entresto. The company’s lead counsel from Bristows explains why and what patentees can take from the ruling. 22 September 2026